ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pfizer INDovation program partners with NIPER Ahmedabad to incubate healthcare startups
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)